

Survivors Journey+

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age: 15 years to 25 years old

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- a diagnosis of a pediatric intracranial tumor
- tumor-directed treatment completed > 12 months ago (treatment included: surgery, radiation, or chemotherapy)
- lives with parent/guardian(s)
- language: English must be the primary spoken language in the home

Exclusion Criteria:

- history of tuberous sclerosis or neurofibromatosis
- treatment < 12 months ago and/or treatment did not include surgery, radiation, or chemotherapy
- history of psychiatric hospitalization
- resides outside of the family home
- history of autism, reactive attachment disorder, psychosis, or other psychiatric diagnoses/conditions associated with significant risk of harm to self or others per caregiver
- English is not the primary language spoken in the home

Conditions & Interventions

Interventions:

BEHAVIORAL: Survivor's Journey+

Conditions:

Pediatric Brain Tumor

Keywords:

pediatric brain tumor survivors, online learning, Adolescent young adult, Family, Digital, Problem Solving

More Information

Description:

The main goal of this pilot randomized controlled trial is to learn if an online program called "Survivors Journey" (SJ+) can help teens and young adults, ages 15-25, who are Pediatric Brain Tumor Survivors (PBTS), and their caregivers, manage everyday challenges better by using skills like problem-solving and coping skills. The main questions it aims to answer are: * Is the SJ+ program rated as feasible (>50% enrollment rate and >75% retention rate) and acceptable (>80% satisfaction rate) by PBTS and their caregivers? * Does the SJ+ program have better outcomes in improving PBTS and caregiver wellbeing in comparison to an internet resource comparison (IRB) made for PBTS and their families? Participants will be randomized into two groups: one group will be given access to the online SJ+ program and receive weekly online coaching sessions, and the other group will be given access to an IRC. Outcomes will be assessed at baseline, treatment completion (~ 3 months post-baseline), and at follow-up six months post-baseline. These outcomes include quality of life, internalizing symptoms, performance-based executive function skills, depression, and family impact.

Contact(s): Zyah Flagg - zyah.flagg@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: NA

IRB Number:

System ID: NCT07321353

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.